A new approach for cellular immunotherapy of nasopharyngeal carcinoma

Nasopharyngeal carcinoma (NPC) is an Epstein-Barr virus (EBV)-associated malignancy that is highly prevalent in Southern China and South-East Asia. EBV-targeted immunotherapy remains a goal in the development of novel treatment strategies. A novel adenoviral polyepitope-based immunotherapy has been...

Descripción completa

Detalles Bibliográficos
Autores principales: Smith, Corey, Khanna, Rajiv
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Landes Bioscience 2012
Materias:
Author's View
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3518531/
https://www.ncbi.nlm.nih.gov/pubmed/23243622
http://dx.doi.org/10.4161/onci.21286
Descripción
Sumario:Nasopharyngeal carcinoma (NPC) is an Epstein-Barr virus (EBV)-associated malignancy that is highly prevalent in Southern China and South-East Asia. EBV-targeted immunotherapy remains a goal in the development of novel treatment strategies. A novel adenoviral polyepitope-based immunotherapy has been developed to rapidly generate high frequency EBV-specific T cells to treat patients with refractory or metastatic disease.

Ejemplares similares